Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs
Molto Valiente, C., Borrell, M., Hwang, T., Gich Saladich, I., Barnadas, A., Amir, E., Kesselheim, A., Tibau, A.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)
Molto Valiente, C., Borrell, M., Ocana Fernandez, A., Templeton, A.J., del Carpio, L.P., Del Paggio, J., Barnadas, A., Booth, C.M., Tibau, A., Amir, E.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval
Borrell Puy, M., Molto Valiente, C., Vokinger, K., Hwang, T., Ocana Fernandez, A., Templeton, A.J., Seruga, B., Gich Saladich, I., Barnadas, A., Amir, E., Tibau, A.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
Riudavets Melia, M., Gabriela Sullivan, I., Barba Joaquín, A., Anguera Palacios, G., del Carpio, L.P., Molto Valiente, C., Camacho Arellano, S.D., Moron Asensio, S., Gomila Pons, P., Andres Granyó, M., Castillo Villegas, D., Facundo Molas, C., Garcia Planella, E., González Blanco, C., Barnadas Molins, A., Gich Saladich, I., Majem Tarruella, M.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1905P Impact of proactive callback in patients with solid tumors receiving systemic therapy: A meta-analysis
Savill, J., Stajer, S., Pathak, N., Malhotra, S., Molto Valiente, C., Nadler, M., Amir, E.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1877P Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis
Pathak, N., Di Iorio, M.R., Savill, J., Berner Wygoda, Y., Malon Gimenez, D., Li, M., Molto Valiente, C., Nadler, M., Mittal, A., Amir, E.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade
Adam, R., Tibau, A., Molto Valiente, C., Seruga, B., Ocaña, A., Amir, E., Templeton, A.J.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1585MO Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies
Bujosa Rodríguez, A., Molto Valiente, C., Tapia, J.C., Gich, I., Barnadas, A., Amir, E., Tibau, A.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1627O - Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015
Rodríguez, A Bujosa, Tapia, J.C., Hwang, T., Valiente, C Molto, Templeton, A.J., Barnadas, A., Amir, E., Tibau, A.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1627OChange in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015
Rodríguez, A Bujosa, Tapia, J C, Hwang, T, Valiente, C Molto, Templeton, A J, Barnadas, A, Amir, E, Tibau, A
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015
Rodríguez, A Bujosa, Tapia, J.C., Hwang, T., Valiente, C Molto, Templeton, A.J., Barnadas, A., Amir, E., Tibau, A.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1564PDMagnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs
Molto Valiente, C, Borrell, M, Hwang, T, Gich Saladich, I, Barnadas, A, Amir, E, Kesselheim, A, Tibau, A
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
252P Impact of informative censoring on the interpretation of progression-free survival (PFS) estimates in phase III randomized trials (RCT) in metastatic breast cancer (MBC)
Wygoda, Y. Berner, Giménez, D. Malón, Di Iorio, M.R., Li, M., Savill, J., Valiente, C. Molto, Amir, E.
Published in ESMO open (01.05.2024)
Published in ESMO open (01.05.2024)
Get full text
Journal Article
1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval
Borrell Puy, M, Molto Valiente, C, Vokinger, K, Hwang, T, Ocana Fernandez, A, Templeton, A J, Seruga, B, Gich Saladich, I, Barnadas, A, Amir, E, Tibau, A
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1562PDMagnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)
Molto Valiente, C, Borrell, M, Ocana Fernandez, A, Templeton, A J, del Carpio, L P, Del Paggio, J, Barnadas, A, Booth, C M, Tibau, A, Amir, E
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1638P Are all leiomyosarcomas created equal? Clinical characteristics and experience of a single reference centre
Teres Lleida, R., Martin Cullell, B., Borrell Puy, M., Bujosa Rodríguez, A., Gallardo Melo, P.G., Molto Valiente, C., Riudavets Melia, M., Aguado Sorolla, M., Piedra Cascon, A., Tapia, J.C., Gavira Diaz, J., Orellana Fernandez, R., Bague Rosell, S., Gallardo Alcañiz, A., Lopez-Pousa, A., Serda, P. Cerda, Sebio Garcia, A.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs
Valiente, C. Molto, Tibau, A., Fernandez, A. Ocana, Templeton, A., del Carpio Huerta, L., Del Paggio, J., Barnadas, A., Booth, C., Amir, E.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours
Molto Valiente, C., Amir, E., Ocana Fernandez, A., Templeton, A., del Carpio Huerta, L., Del Paggio, J., Barnadas, A., Booth, C., Tibau, A.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
Clinical benefit of randomized controlled trials (RCT) supporting US Food and Drug Administration (FDA) conversion from accelerated to full approval
Puy, M. Borrell, Valiente, C. Molto, Fernandez, A. Ocana, Templeton, A., Seruga, B., Gich, I., Barnadas, A., Amir, E., Tibau, A.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
1409PAssociation of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
Riudavets Melia, M, Gabriela Sullivan, I, Barba Joaquín, A, Anguera Palacios, G, del Carpio, L P, Molto Valiente, C, Camacho Arellano, S D, Moron Asensio, S, Gomila Pons, P, Andres Granyó, M, Castillo Villegas, D, Facundo Molas, C, Garcia Planella, E, González Blanco, C, Barnadas Molins, A, Gich Saladich, I, Majem Tarruella, M
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article